(NASDAQ: OBIO) Orchestra Biomed Holdings's forecast annual revenue growth rate of 83.64% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 115.73%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.06%.
Orchestra Biomed Holdings's revenue in 2026 is $2,818,000.On average, 10 Wall Street analysts forecast OBIO's revenue for 2026 to be $208,241,928, with the lowest OBIO revenue forecast at $149,405,678, and the highest OBIO revenue forecast at $272,724,651. On average, 7 Wall Street analysts forecast OBIO's revenue for 2027 to be $158,609,429, with the lowest OBIO revenue forecast at $33,201,262, and the highest OBIO revenue forecast at $302,368,635.
In 2028, OBIO is forecast to generate $1,311,732,166 in revenue, with the lowest revenue forecast at $475,884,753 and the highest revenue forecast at $2,190,718,633.